Sophie Vandebroek
About Sophie Vandebroek
Sophie V. Vandebroek, PhD (age 63), is an independent director of Revvity (RVTY) and a member of the Audit Committee; she joined the board in 2024 and qualifies as an “audit committee financial expert.” Her background spans senior technology leadership roles at IBM (VP, Emerging Technology Partnerships; COO, IBM Research), Xerox (CTO/Corporate VP; President, Xerox Innovation Group; Chief Engineer), and academia (MIT School of Engineering visiting scholar), with deep expertise in AI, cybersecurity, sustainability, and R&D portfolio management. She holds bachelor’s and master’s degrees in electro-mechanical engineering from KU Leuven and a PhD in electrical engineering from Cornell University .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| IBM Corporation | Vice President, Emerging Technology Partnerships | 2018–2019 | Led partnerships in emerging tech; focus on AI/cybersecurity/business processes |
| IBM Research | Chief Operating Officer | 2017–2018 | Operational leadership of global research organization |
| MIT School of Engineering | Inaugural Visiting Scholar | 2019–2020 | Academic collaboration and thought leadership |
| Xerox Corporation | CTO & Corporate VP; President, Xerox Innovation Group; Chief Engineer | — | Oversaw global research centers, including PARC; technology strategy and innovation |
| Strategic Vision Ventures, LLC | Founder & Owner | Since 2021 | Technology consulting; strategic advisory |
External Roles
| Organization | Role | Public/Private | Tenure/Notes |
|---|---|---|---|
| IDEXX Laboratories, Inc. | Director | Public | Current |
| Wolters Kluwer N.V. | Director | Public | Current |
| Inari Agriculture, Inc. | Director | Private | Current |
| Analogic Corporation | Director | Public (former) | Formerly served |
| Flanders AI Research Program | Chair, Advisory Committee | — | Current |
| KU Leuven | Honorary Professor | — | Appointed 2021 |
| IEEE | Fellow | — | Current |
Board Governance
- Independence and roles: Independent director; Audit Committee member; designated “audit committee financial expert” by the board .
- Attendance and engagement: The board met six times in FY2024; each director attended ≥75% of combined board/committee meetings; all directors attended the 2024 annual meeting (virtual) .
- Committee load and activity: Audit Committee held eight meetings in FY2024; current Audit members include Chair Sam Chapin, Michael Klobuchar, Michel Vounatsos, Pascale Witz, and Dr. Vandebroek. All Audit members are NYSE-independent; none serves on more than two other public company audit committees .
- Leadership structure: Independent Non-Executive Chair; independent directors meet in executive sessions before/after each regularly scheduled board meeting .
- Determination of independence: Board conducts annual independence review under NYSE standards; Dr. Vandebroek determined independent .
Fixed Compensation (Director)
| Component | 2024 Policy/Amount | Paid to S. Vandebroek (2024) | Notes |
|---|---|---|---|
| Annual cash retainer | $90,000 cash, paid quarterly | $82,500 | Prorated for partial service; no meeting fees |
| Committee chair fees | Audit: $25,000; Comp: $20,000; NCG: $15,000 | $0 | Not a chair |
| Non-Exec Chair retainer | $90,000 (Chair only) | N/A | — |
| Charitable match | Up to $5,000 annually | $5,000 | Through Revvity Foundation |
Performance Compensation (Director)
| Component | Structure | 2024 Detail for S. Vandebroek |
|---|---|---|
| Performance-based pay | Not applicable for non-employee directors | Director equity is time-based; no performance metrics apply |
Director Equity Grants (2024)
| Grant Type | Grant Date | Shares/Units | Grant Date Fair Value | Vesting/Terms |
|---|---|---|---|---|
| Annual stock (common shares) | May 1, 2024 | 1,218 shares | $124,967 | Fully unrestricted; no vesting |
| Annual RSUs | May 1, 2024 | 977 RSUs | $99,967 | Vest 100% at next annual meeting; earlier on death/disability/qualifying retirement or within 12 months post-COC if service ends |
| New director pro-rata stock (common shares) | Feb 15, 2024 | 264 shares | $27,474 | Pro-rated for service Feb 1–Apr 23, 2024 |
| New director pro-rata RSUs | Feb 15, 2024 | 217 RSUs | $22,522 | Pro-rated; vest aligned to 2024 board year end |
| 2024 equity policy | — | Non-Chair target: $225,000 total equity (stock + RSUs) from 2024; Chair at separate levels | Increased by $25,000 effective Apr 23, 2024; no changes for 2025 |
Other Directorships & Interlocks
| Company | Sector | Role | Potential Interlock/Notes |
|---|---|---|---|
| IDEXX Laboratories, Inc. | Vet diagnostics | Director | Current public board; no related-party transactions disclosed involving Dr. Vandebroek at Revvity |
| Wolters Kluwer N.V. | Information services | Director | Current public board; within Revvity overboarding policy limits |
| Inari Agriculture, Inc. | Ag-biotech | Director | Private company board |
| Analogic Corporation | Med-tech | Director (former) | Former public board |
Expertise & Qualifications
- Technology and innovation operator with oversight of global research centers (including PARC), and deep domain in sustainability, AI, cybersecurity, and business processes; perspective spans enterprise partnerships and R&D portfolio governance .
- Financial oversight credentials: Board designated “audit committee financial expert”; financially literate per NYSE rules .
- Academic/industry recognition: IEEE Fellow; Honorary Professor at KU Leuven .
- Education: BS/MS in electro-mechanical engineering (KU Leuven); PhD in electrical engineering (Cornell) .
Equity Ownership
| Item | Status |
|---|---|
| Beneficial ownership (Feb 14, 2025) | 2,676 shares; no stock-based holdings; 0 acquirable within 60 days; total 2,676; <1% of class |
| Unvested director RSUs at 12/29/2024 | 977 RSUs |
| Ownership guidelines | Directors must hold ≥5x annual cash retainer ($450,000) within 5 years; all directors in compliance as of Feb 14, 2025 |
| Hedging/derivatives | Prohibited for all directors/employees; short sales and derivatives banned by policy |
| Pledging | Officers may not pledge company stock; policy text specifies officers; hedging ban applies to directors |
Insider Trades
| Period | Notes |
|---|---|
| FY2024 Section 16(a) | Company disclosed one late Form 4 for a different individual; no delinquencies noted for Dr. Vandebroek |
Governance Assessment
- Board effectiveness: Strong fit for Audit; designated financial expert and deep technology/AI experience strengthen oversight of cyber, data, and R&D-related risks. Audit met 8x in FY2024; board met 6x; ≥75% attendance met; annual meeting attendance confirmed .
- Independence and conflicts: Board determined independent; no related-party transactions involving her disclosed; securities policy bans hedging/derivatives, mitigating alignment risks .
- Ownership alignment: Mix of cash ($82.5k in 2024) and time-based equity (~$274.9k FV grants in 2024) with annual RSU vesting at the next AGM; directors subject to 5x retainer stock ownership rule, with compliance affirmed as of Feb 14, 2025 .
- Overboarding/interlocks: Revvity policy limits to ≤3 other public boards; her two current public boards (IDEXX, Wolters Kluwer) are within policy; Audit Committee service cap on external audit committees also met .
- Shareholder sentiment signal: 2024 say-on-pay support at 95.7% indicates broad investor support for governance/comp design; though executive-focused, positive for overall governance climate in which she serves .
RED FLAGS: None disclosed specific to Dr. Vandebroek. No related-party transactions identified; no Section 16(a) delinquencies noted for her; within overboarding limits; hedging/derivatives prohibited by policy .